TABLE 1.

SARS patient demographics and treatment and clinical characteristics

ParameteraValue for patient group
AllNonsevere SARSSevere SARS
SARS patient demographics and disease course
    Total no. of patients503020
    No. of males/no. of females22/2810/2012/8
    Median yr of age (range)48 (24-83)44 (24-80)63 (31-83)
    Median no. of days of illness (range)16 (7-136)15 (7-27)38 (15-136)b
    No. of patients with:
        Increased O2 supportc (%)20 (40)0 (0)20 (100)
        Mechanical intubation (%)16 (32)0 (0)16 (80)
    No. of patients who died (%)6 (12)0 (0)6 (32)
SARS patient clinical parameters
    Incidence of fever at presentation (%)50 (100)30 (100)20 (100)
    Median DSO for peak temp (range)4 (3-9)3 (3-8)4 (3-9)
    Median no. of days of duration of fever of ≥38°C (range)11 (3-36)8 (3-15)18 (6-36)b
    No. of patients with CXR positive for infiltrate at any time (%)47 (94)27 (90)20 (100)
    Median DSO for peak chest radiographic involvement (range)6 (1-21)6 (1-21)7 (2-12)
    Median no. of days from first positive CXR to improvement (range)10 (1-108)6 (1-23)20 (12-108)b
    Median DSO for SO2 nadir (range)8 (4-24)8 (4-18)9 (5-24)b
    Median % SO2 at nadir (range)93 (71-96)94 (92-96)82 (71-90)b
    No. of patients with severe hypoxemia (i.e., SO2 < 91%) (%)19 (38)0 (0)19 (95)
    Median duration of hypoxemia (SO2 ≤ 96%) in days (range)16 (8-35)13 (8-28)30 (15-35)b
    DSO for median peak viral titer (range) in:
        Stool12 (5-18)12 (5-18)13.5 (6-16)
        Nasopharynx7.5 (7-8)7.5 (7-8)7.5 (7-8)
    Incidence of lymphopenia (ALC ≤ 1,000/mm3) (%)48 (96)28 (93)20 (100)
    Median DSO for peak lymphopenia (range)8 (3-23)5 (3-17)14 (7-23)
    Median no. of days for duration of lymphopenia (range)9 (3-60)7 (3-18)27 (7-60)b
SARS patient treatment
    No. of patients given corticosteroid treatment (%)37 (74)17 (57)20 (100)
    Median DSO of first corticosteroid dose (range)6 (2-13)7 (2-13)6 (2-12)
    Median no. of days of corticosteroid treatment (range)8 (3-114)8 (3-18)9 (3-114)b
    Oral prednisone treatment
        No. of patients given treatment (%)26 (52)17 (57)9 (45)
        Median peak daily dosage in mg (range)100 (50-200)100 (50-200)100 (50-200)
    Intravenous methylprednisolone treatment
        No. of patients given treatment (%)27 (54)8 (27)19 (95)
        Median peak daily dosage in mg (range)125 (50-500)80 (80-500)375 (50-500)
  • a DSO, days since onset of symptoms; CXR, chest X-ray; ALC, absolute lymphocyte count; SO2, arterial O2 saturation.

  • b Data from surviving patients only.

  • c Supplemental O2 rate of ≥4 liters/min or mechanical ventilation.